IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that Vicente
Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at
the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017
at 1:40 p.m. Eastern Time in New York, NY. Dr. Anido will provide an
Aerie overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two lead product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA filing for
Rhopressa™ (netarsudil ophthalmic solution) 0.02% was resubmitted to the
FDA in February 2017. Aerie's second product candidate, Roclatan™
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed
dose combination of Rhopressa™ and latanoprost, a widely prescribed
prostaglandin analogue. Roclatan™ currently has two Phase 3 registration
trials underway, named Mercury 1 and Mercury 2. If these trials are
successful, an NDA for Roclatan™ is expected to be filed in late 2017 or
early 2018. Aerie is also focused on the development of additional
product candidates and technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328005003/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media